In another study that will prompt people to question CDC and FDA COVID treatment guidance, researchers have found that ivermectin is associated with decreased mortality compared with remdesivir.
The International Journal of Infectious Diseases published the study findings.
In the study, researchers at the University of Miami reviewed a federal database tracking adults testing positive for COVID between January 2020 and July 2021.
Researchers compared the mortality rates of those who used ivermectin but not remdesivir with those who used remdesivir but not ivermectin.
According to The Epoch Times, variables that could impact “COVID-19 survival outcomes, including age, gender, race, ethnicity, nicotine use, diabetes mellitus, obesity, chronic lower respiratory disease, and ischemic heart diseases tocilizumab, glucocorticoids, or ventilator use, were controlled.
The study found that “after using propensity score matching and adjusting for potential confounders, ivermectin, when compared to remdesivir, was associated with reduced mortality.”
The report stated: “To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin.”
According to the study, the “risk difference…is statistically significant.”
Out of a database of 1,761,060 COVID patients, approximately 42,000 met the qualifications for the study. Symptom severity also factored into the analysis.
The study was professionally coordinated and included double-blind placebo controls. However, the magnitude of the findings, which contradict current CDC and FDA treatment protocols for COVID, require further study. The report read:
“Further double-blinded placebo-controlled RCTs with large samples are required for a definite conclusion. In the future, if more publications are published with similar results to the current analyses, the certainty of evidence will increase.”
The Epoch Times report noted that “The World Health Organization features ivermectin on its List of Essential Medicines.” However, pharmacies and hospitals widely refuse to make ivermectin available.
Leading the push for change, the Front Line COVID Critical Care Alliance and the British Ivermectin Recommendation Development Group advocate using ivermectin in treating COVID.
More than 150 studies (103 are peer-reviewed) show ivermectin to be beneficial in treating COVID.
Studies also show that remdesivir is linked to kidney disease, gastrointestinal symptoms, and other severe side effects. In late 2020, the WHO discouraged the use of remdesivir for treating COVID. The FDA and CDC, however, continue to recommend the use of remdesivir for treating “moderate to severe” cases of COVID.
Biden administration officials, including Dr. Anthony Fauci, do not advocate for the use of ivermectin. In September 2021, the American Medical Association, the American Pharmacists Association, and the American Society of Health-System Pharmacists issued a joint statement noting ivermectin should not be used to treat COVID.
Scroll down to leave a comment and share your thoughts.
